Molecules of the Month

June 2022

A SETD2 inhibitor with Fast Track Status for hematological malignancies, a CNS-penetrating, ATP-competitive LRRK2 inhibitor for Parkinson’s disease, and an oral nonsteroidal mineralocorticoid receptor antagonist are some examples of this month's MOTM. In the slide deck, you'll find a small molecule that modulates a protein that has only been targeted with antibodies so far and a drug that takes advantage of the glutamate NMDA receptor hypofunction hypothesis. Check out the ten molecule minireviews in the slide deck, which covers:

  • Where are all of the Molecules of the Month in clinical development?

  • What's known about differentiation from previous molecules?

  • Where did the starting points come from?

  • Industry context, mechanism of action details, and more…

Thanks to reviewers Bryan McKibben, PhD and Chris Gampe, PhD for their nominations and commentary this month.

twitterlinkedinemail

MOTY Nominees

Molecule of the Year

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.